Repository of Research and Investigative Information

Repository of Research and Investigative Information

Kurdistan University of Medical Sciences

Sustained-release methylphenidate in methamphetamine dependence treatment: A double-blind and placebo-controlled trial

(2015) Sustained-release methylphenidate in methamphetamine dependence treatment: A double-blind and placebo-controlled trial. DARU, Journal of Pharmaceutical Sciences.

Full text not available from this repository.

Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Background: The objective of this randomized, double-blind, placebo-controlled study was to evaluate the efficacy of sustained-release methylphenidate (MPH-SR) in treatment of methamphetamine dependence. Methods: Fifty-six individuals who met DSM-IV-TR criteria for methamphetamine dependence participated in this 10-week trial. The participants were randomly allocated into two groups and received 18 to 54 mg/day sustainedreleased methylphenidate or placebo for 10 weeks. Craving was evaluated by a visual analogue craving scale every week. Urinary screening test for methamphetamine was carried out each week. The Beck Depression Inventory-II (BDI-II) was used to monitor participant depressive symptoms at baseline and bi-weekly during the treatment period. Results: At the end of the trial, the MPH-SR group was less methamphetamine positive compared to the placebo group and the difference was significant (p = 0.03). By the end of the study, MPH-SR group showed significantly less craving scores compared to the placebo group MD (95% CI) = -10.28(0.88-19.18), t(54) = 2.19, p = 0.03. There was greater improvement in the depressive symptoms scores in the intervention group compared to the placebo group MD (95% CI) =2.03(0.31-3.75), t (54) =2.37, p = 0.02. Conclusion: Sustained-released methylphenidate was safe and well tolerated among active methamphetamine users and significantly reduced methamphetamine use, craving and depressive symptoms. © 2015 Rezaei et al.

Item Type: Article
Keywords: methylphenidate; placebo, adult; aged; anxiety; Article; Beck Depression Inventory; controlled study; decreased appetite; depression; dizziness; double blind procedure; drug craving; drug efficacy; drug safety; drug tolerability; DSM-IV-TR; female; headache; human; insomnia; irritability; major clinical study; male; methamphetamine dependence; myalgia; nausea; randomized controlled trial; screening test; side effect; stomach pain; sustained release formulation; treatment duration; urinalysis; visual analog scale
Journal or Publication Title: DARU, Journal of Pharmaceutical Sciences
Volume: 23
Number: 1
Publisher: BioMed Central Ltd.
Identification Number: 10.1186/s40199-015-0092-y
ISSN: 15608115
Depositing User: مهندس جمال محمودپور
URI: http://eprints.muk.ac.ir/id/eprint/870

Actions (login required)

View Item View Item